SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: DorianGray
Search This Board: 
Last Post: 2/23/2017 1:02:25 PM - Followers: 197 - Board type: Free - Posts Today: 0




Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

Archexin® Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth, survival, angiogenesis, and drug resistance. Archexin has completed a Phase I clinical trial in cancer patients and was shown to be safe and well tolerated. The dose-limiting toxicity was grade 3 fatigue. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated and demonstrated a preliminary efficacy signal with a median survival of 9.1 months. Rexahn initiated an additional Phase IIa clinical trial for Archexin in combination with everolimus to treat cancer patients with metastatic renal cell carcinoma in January 2014.

RX-3117 RX-3117 is a next generation cancer cell specific nucleoside that inhibits DNA and RNA synthesis and induces apoptotic cell death by a mechanism distinct from existing non-selective nucleoside drugs currently used to treat cancer patients. Preclinical studies have shown RX-3117 to be effective in inhibiting the growth of solid tumors in the pancreas, lung, colon, kidney and others and to be effective in gemcitabine resistant cancer cell lines. An exploratory Phase I clinical trial in cancer patients was conducted in Europe in 2012 and demonstrated that RX-3117 is orally bioavailable with no reported adverse events were reported over the dose range tested. Rexahn initiated a Phase Ib clinical trial in cancer patients with solid tumors in January 2014..

 SupinoxinTM (RX-5902) SupinoxinTM is an orally administered first-in-class small molecule that inhibits the growth of multiple types of human cancer cells through inhibition of phosphorylated p68 which is selectively expressed in cancer cells. Preclinical studies to date have shown SupinoxinTM to be effective in blocking tumor progression and metastasis for melanoma, cancers of the ovary, kidney and pancreas. A Phase I clinical trial with SupinoxinTM in cancer patients with solid tumors began in August 2013. This trial is a multi-center study, designed to evaluate the safety, tolerability, and maximal tolerated dose (MTD) and preliminary efficacy in patients with solid tumors.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.


 Rexahn  Pipeline


Management Team

Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University

Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.

[email protected]

Maxim Group, LLC
Echo He, MD, Ph.D.

[email protected]

H. C. Wainwright & Co., LLC
Andrew Fein

[email protected]   

Tricia Truehart
(646) 378-2953
[email protected]

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RNN News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 02/13/2017 04:47:45 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:53:52 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:51:41 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:48:58 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:46:15 PM
#3170  Sticky Note * * $RNN Video Chart 02-14-17 * * ClayTrader 02/14/17 04:34:44 PM
#3188   Nice steady progress. Nice to c it basing ttubular 02/23/17 01:02:25 PM
#3187 Theo 02/23/17 09:15:23 AM
#3186   No idea - where did our bulls go? DorianGray 02/21/17 10:29:01 PM
#3185   Anyone know how the presentation went ttubular 02/21/17 07:32:21 PM
#3184   Strong day! The shorts tried an early takedown DorianGray 02/17/17 09:12:32 PM
#3183   Nice to see it stop the bleeding n ttubular 02/17/17 04:59:00 PM
#3182   At least there was some excitement this week ttubular 02/17/17 01:38:33 AM
#3181   What do you think is the cause for Valensio 02/16/17 10:55:32 PM
#3180   I'm up 2 cents already..boy am I ever smart. shotgun 02/16/17 09:08:22 PM
#3179   bought some at 23 cents GTC limit shotgun 02/16/17 04:21:28 PM
#3178   Is there anyone out there that can report ttubular 02/16/17 10:25:57 AM
#3177   * * $RNN Video Chart 02-15-17 * * ClayTrader 02/15/17 10:49:42 PM
#3176   Hard to say if news leaked or this Valensio 02/15/17 02:36:28 PM
#3175   Very strange to have a volume surge like ttubular 02/15/17 01:33:33 PM
#3174   Well the data on their trials is really DorianGray 02/15/17 01:15:12 PM
#3173   My guess on today's action There was some rumor ttubular 02/15/17 12:19:38 PM
#3172   hopefully dannie30 02/15/17 09:56:51 AM
#3171   Wht will happen today more consolidating n base here ttubular 02/15/17 07:00:48 AM
#3170   * * $RNN Video Chart 02-14-17 * * ClayTrader 02/14/17 04:34:44 PM
#3169   RNN is holding up great today, if it DorianGray 02/14/17 02:15:52 PM
#3168   let's hope we see a close over .28 WeGetMoney 02/14/17 01:34:24 PM
#3167   Technicals : WeGetMoney 02/14/17 11:38:24 AM
#3166   looks good now imo. dannie30 02/14/17 10:04:24 AM
#3165   Nice early action almost all buys 52 k volume ttubular 02/14/17 08:17:33 AM
#3164   no reason for the up tick..probably down hard shotgun 02/13/17 07:50:04 PM
#3163   lol Dorian, AH = Amateur hour. Isn't that Valensio 02/13/17 07:48:05 PM
#3162   AH = Amateur Hour...don't get caught up in DorianGray 02/13/17 06:51:10 PM
#3161   No I'm not sure what the current short Valensio 02/13/17 05:55:54 PM
#3160   anyone know why this is stuck at 0.3189 me boojum 02/13/17 05:27:32 PM
#3159   About 250k traded in AH up .03 Wow ttubular 02/13/17 05:24:28 PM
#3158   AH mkt lovin this. had to get me boojum 02/13/17 05:14:41 PM
#3157   Thanks for video, you're well known in the community. DorianGray 02/13/17 05:14:37 PM
#3156 WeGetMoney 02/13/17 04:58:11 PM
#3155   * * $RNN Video Chart 02-13-17 * * ClayTrader 02/13/17 04:34:46 PM
#3154   Wow what a nice day hope this ttubular 02/13/17 03:57:21 PM
#3153   RNN 0,2871 harmsen 02/13/17 03:34:42 PM
#3152   I gave the site a facelift, it's been DorianGray 02/13/17 03:33:24 PM
#3151   RNN 0,2827 harmsen 02/13/17 03:32:57 PM
#3150   RNN 0,276 harmsen 02/13/17 03:30:33 PM
#3149   4 years back from 0,30 to 1,78 in harmsen 02/13/17 03:19:06 PM
#3148   Do you know what the short interest on the gipper 02/13/17 01:48:28 PM
#3147   Shorts are covering, helping cause this spike. But Valensio 02/13/17 12:57:13 PM
#3146   500k bid @ some whales wanting in! the gipper 02/13/17 12:56:10 PM
#3145   No - these biotech's are all wild cards, DorianGray 02/13/17 12:48:40 PM
#3144   Can anyone guess what is causing the huge ttubular 02/13/17 11:46:51 AM
#3143   Best case today it consolidates around this .24/.25 DorianGray 02/13/17 11:30:20 AM
#3142   RNN 0,26 harmsen 02/13/17 10:29:37 AM
#3141   Wow we r off to the races !!!! Something ttubular 02/13/17 10:11:07 AM
#3140   Nice premarket action 77k traded up .02. Go ttubular 02/13/17 08:24:58 AM
#3139   yeah, a few years ago this stock was shotgun 02/10/17 09:53:57 PM